Infection in the first 2 years of life: protective effect
|
Dockerty et al13,a (1999) |
New Zealand |
CC |
Eye infection |
ALL |
OR 0.2 (0.1;0.7) |
Mckinney et al44 (1999) |
Scotland |
CC |
Skin infection |
ALL CL |
OR 0.2 (0.05;0.87) OR 0.2 (0.05;0.87) |
Neglia et al48 (2000) |
USA |
CC |
Ear infection |
ALL |
Ear infection episodes reduced the risk: p trend = 0.026 |
Chan et al10,a (2002) |
Hong Kong |
CC |
Roseola and/or fever + rash |
ALL |
OR 0.33 (0.16;0.68) |
Perrilat et al52,a (2002) |
France |
CC |
Surgical procedures: ear, nose, throat |
CL |
OR 0.4 (0.2;0.9) |
Jourdan-da Silva et al25,a (2004) |
France |
CC |
≥4 gastrointestinal infections |
ALL |
OR 0.1 (0.03;0.6) |
Rosembaum et al66,a (2005) |
New York State |
CC |
Diarrhoea |
ALL |
OR 0.69 (0.48;0.99) |
Simpson et al75,a (2007) |
UK |
CC |
Eye infection |
ALL |
OR 0.7 (0.5;0.9) |
Rudant et al67,a (2010) |
France |
CC |
Otitis; Bronchiolitis/other lower respiratory tract infections; Gastroenteritis |
ALL |
OR 0.7 (0.5;1.0) OR 0.3 (0.2;0.6) OR 0.3 (0.1;0.8) |
Urayama et al81 (2011) |
California |
CC |
Ear infection: non-Hispanic children; Hispanic children |
ALL |
OR 0.39 (0.17;0.91) OR 0.48 (0.27;0.83) |
|
Infection in the first 2 years of life: increased risk |
|
Dockerty et al13
,
a (1999) |
New Zealand |
CC |
Influenza |
CL ALL |
OR 6.80 (1.81;25.66) OR 6.0 (1.4;26.2) |
Perrilat et al52,a (2002) |
France |
CC |
Mumps |
CL |
OR 3.2 (1.1;9.0) |
Rosembaum et al66,a (2005) |
New York State |
CC |
Otitis in the second year of life |
ALL B lineage |
OR 1.56 (1.02;2.37) |
Roman et al64 (2007) |
UK |
CC |
Upper respiratory tract infection Fungal infection |
ALL |
OR 1.3 (1.0;1.7) OR 1.9 (1.1;3.2) |
Simpson et al75,a (2007) |
UK |
CC |
At least one infection |
ALL |
OR 1.6 (1.1;2.2) |
Cardwell et al9 (2008) |
UK |
CC |
Upper respiratory tract infections; Chickenpox |
ALL |
OR 1.59 (1.02;2.49) OR 2.62 (1.12;6.13) |
Rudant et al67,a (2010) |
France |
CC |
Upper respiratory tract infections |
ALL |
OR 1.6 (1.3;2.0) |
|
Infection in the first 2 years of life: non-significant effects or no association |
|
Van Steensel-Moll et al82 (1986) |
Netherlands |
CC |
Common colds; Fever |
ALL |
RR 0.8; p > 0.05; RR 0.9; p > 0.05 |
Naumburg et al47 (2002) |
Sweden |
CC |
History of infection in the postpartum |
CL |
OR 1.0 (0.50;2.04) |
|
Infection at any time prior to the diagnosis: protective effect |
|
Schlehofer et al68,a (1996) |
Germany |
CC |
Herpes labialis |
CL |
RR 0.38 (0.15;0.96) |
Schuz et al70,a (1999) |
Germany |
CC |
Chickenpox |
AL |
OR 0.8 (0.7;1.0) |
Ma et al38 2(005) |
California |
CC |
Ear infection (in non-Hispanic) |
c-ALL |
OR 0.32 (0.14;0.74) |
|
Infection at any time prior to the diagnosis: increased risk |
|
Mckinney et al43 (1987) |
UK |
CC |
Number of illness episodes |
CL |
RR 1.9 (1.0;3.4) |
Jourdan-da Silva et al25,a (2004) |
France |
CC |
Rubella |
ALL |
OR 2.4 (1.4;4.1) |
|
Infection at any time prior to the diagnosis: non-significant effect or no association |
|
Macarthur et al40 (2008) |
Canada |
CC |
Mumps Measles |
ALL |
OR 0.57 (0.13;2.52) OR 0.62 (0.25;1.27) |
|
Infection at diagnosis or in the year before diagnosis: increased risk |
|
|
Schuz et al70,a (1999) |
Germany |
CC |
Bronchitis Pneumonia |
c-ALL |
OR 1.9 (1.3;2.7) OR 2.6 (1.4;4.8) |
Chan et al10,a (2002) |
Hong Kong |
CC |
Tonsillitis |
c-ALL |
OR 2.96 (1.32;6.66) |
Kroll et al29 (2006) |
Britain |
ECO |
Influenza |
c-ALL |
Influenza epidemic preceded peak of c-ALL |
|
Infection at diagnosis or in the year before diagnosis: laboratory analysis |
|
Schlehofer et al68,a (1996) |
Germany |
CC |
Epstein-Barr Virus Parvovirus B-19 Adeno-associated virus type 2 Human herpes virus type 6. |
CL |
RR 2.05 (0.99;4.23) RR 0.48 (0.14;1.69) RR 0.66 (0.29;1.50) RR 1.11 (0.54;2.28) |
Petridou et al56 (2001) |
Greece |
CC |
Epstein-Barr virus Human herpes virus type 6 Mycoplasma Parainfluenza1,2,3 |
ALL |
OR 0.4 (0.2;0.8) OR 0.5 (0.3;0.9) OR 0.1 (0.0;0.7) OR 1.9 (1.1;3.2) |
Mahjour et al41 (2010) |
Iran |
CC |
Herpes Simplex Viruses 1 and 2; Epstein-Barr Virus; hepatitis B Virus |
ALL |
The prevalence of antibodies against HBsAg (p = 0.002), HSV1 (p < 0.0001), VCA (p = 0.021) and EA (p < 0.0001) antigens of EBV were higher in ALL patients. |
Sehgal et al71 (2010) |
India |
CC |
Epstein Barr Virus |
ALL |
Significant increase in EBV in ALL patients (p < 0.05) |